WCG continues acquisitive streak with biostatistical consultancy buyout

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/IvonneW)
(Image: Getty/IvonneW)

Related tags: WCG, Statistics Collaborative

WCG adds to its portfolio of solutions for clinical trial sponsors by acquiring Statistics Collaborative.

Statistical Collaborative, which is based in Washington, D.C., US, provides biostatistical consulting services to companies developing new drugs and biologics.

In particular, the company offers expertise in trial design, reporting for data monitoring committees, data analysis, and consultation for US Food and Drug Administration presentations. It also works with companies when designing preclinical studies and non-clinical research.

Through the acquisition, WCG will take onboard all of Statistics Collaboration’s staff members and retain the same leadership structure. While the company name will change to simply be prefixed by ‘WCG’.

The financial details of the deal were not disclosed, but WCG will provide its new subsidiary with “access to capital, additional clinical development expertise, and corporate operational support,”​ WCG stated.

For WCG, the strategy continues where 2019 left off – as it consistently adds to its solutions through small-scale acquisitions, year-on-year.

Last year, WCH acquired PharmaSeek​ and Velos’ CTMS internet platform​. A similar pattern unfolded in 2018, when it added ACI Clinical​, and KMR Group and MCC​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars